Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer.

Elife · 2021 · PMC8169110 · PMID 34060472

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

The presentation of CSSTRESAC as a novel targeting agent for Triple Negative Breast Cancer and, one would expect, for other tumors with a strong M2 TAM response is potentially quite significant.

also in 5,695 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.